Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 3/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.32 |
| ▸ | CTSD | P07339 | 3/20 | 0.32 |
| ▸ | FSHR | P23945 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 5/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449911 | 0.84 | NOTUM (0.40) | FGFR4FSHRP2RY1MAPT | |
| SCHEMBL16101298 | 0.81 | AKR1B1 (0.46) | FGFR4MAPKAPK2AKR1B1MAPT | |
| SCHEMBL16101427 | 0.80 | FGFR4 (0.43) | FGFR4MAPKAPK2 | |
| SCHEMBL691049 | 0.78 | NR1H2 (0.42) | FGFR4EGFRP2RY1 | |
| SCHEMBL89951 | 0.76 | FGFR4 (0.33) | FGFR4BACE1CTSDJAK3P2RY1 | |
| SCHEMBL12519575 | 0.75 | EGFR (0.47) | FGFR4EGFRJAK3 | |
| SCHEMBL16101786 | 0.74 | MAPKAPK2 (0.47) | MAPKAPK2MAPT | |
| SCHEMBL20987885 | 0.74 | MAPT (0.30) | FGFR4MAPT | |
| SCHEMBL448820 | 0.74 | MAPT (0.38) | BACE1CTSDMAPT | |
| SCHEMBL427069 | 0.69 | NOTUM (0.43) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | FGFR4 2840/4885MAPKAPK2 7/4885BACE1 4071/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | FGFR4 2840/4885MAPKAPK2 7/4885BACE1 4071/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | FGFR4 2840/4885MAPKAPK2 7/4885BACE1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.